"We believe STAR0602 could be game-changing for patients who fail to respond to checkpoint inhibitors, because it promotes antitumor activity via a very different mechanism, characterized by expansion of a new subset of memory Vβ T cells that reinvigorate the T cell response to tumors." ICYMI: As a follow up to the paper published in Science Translational Medicine, Marengo's CSO Andrew Bayliffe spoke with the team at ACIR.
Marengo Therapeutics
Biotechnology Research
Cambridge, MA 4,469 followers
A new frontier in the fight against cancer– the right activation of the right immune cells
About us
Marengo Therapeutics, a clinical stage biotech company, is pioneering an entirely new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay. For more information visit our website (https://www.marengotx.com)
- Website
-
https://www.marengotx.com
External link for Marengo Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Specialties
- Immuno-oncology, Oncology, T cell biology, Immunology, Drug Development, and Biologics
Locations
-
Primary
840 Memorial Drive
4th Floor
Cambridge, MA 02139, US
Employees at Marengo Therapeutics
-
Madan Katragadda Ph.D., MBA
VP, Antibody Technologies and CMC at Marengo Therapeutics
-
Claire Coleman
Vice President Program Management at Marengo Pharmaceuticals
-
Zhen Su, MD MBA
Physician Scientist, Entrepreneur and CEO at Marengo Therapeutics
-
Kevin Chin
Chief Medical Officer, Marengo Therapeutics
Updates
-
This summer, we’ve been extremely fortunate to have Keana Ramos Baptista on our team. Keana, who is about to enter her junior year at Boston University, has spent the past few months assisting the Marengo team in the office and the lab. Her contributions have made her an invaluable member of our People & Culture team. We met Keana through Project Onramp , a wonderful program by Life Science Cares Boston. We are truly grateful for the dedication and enthusiasm she has brought to her internship. We are excited to see all the amazing things Keana will accomplish in the future and wish her the very best. Learn more about the program here: https://projectonramp.us
-
Attending DIA (Drug Information Association)'s Global Annual Meeting in San Diego? Join Marengo's Chief Development Officer Ke Liu , MD, PhD for their panel session to interpret FDA guidance, discuss trends, and share their own experiences for study design in cell and gene therapy trials.
-
Marengo Therapeutics reposted this
Wonderful discussion on expediting the #platform to #pipeline journey with Leslie J Williams HC Bioscience, Inc., Rachel W. Humphrey, MD Normunity, Geoffrey McDonough Generation Bio, Mittul Mehta TEVOGEN BIO, Zhen Su, MD MBA Marengo Therapeutics at #longwoodhealthcareleaders Longwood Fund
-
Marengo Therapeutics reposted this
What an honor to host Brad Loncar (BiotechTV) on site at Marengo Therapeutics and chat about our recent $1.2B partnership with Ipsen focused on our next generation Precision T-cell engager approach to bring more targeted IO therapeutics to "COLD" tumor. Let's to it together as One Team!
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Marengo Therapeutics' CEO Zhen Su, MD MBA on the expansion of a partnership with Ipsen to activate T-cells against cold tumors. He describes how to succeed against cold tumors where T-cells are not in abundance to begin with, you have to activate and then drive them to the tumor. Full video: https://lnkd.in/gyC4EEY9 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
🌟 Nasdaq celebrates the extension of the strategic partnership between Marengo Therapeutics and Ipsen! This collaboration continues to drive innovation and growth in the biotech sector for better treatment for patients, setting new standards for success. 🚀 A special thanks to the Nasdaq team for this honor! ATP (Apple Tree Partners) #Nasdaq #Marengo #Ipsen #Biotech #Partnership #oncology
-
Marengo Therapeutics reposted this
Exciting News! Today Marengo Therapeutics jointly announced our expanded partnership with Ipsen to advance precision T cell engagers from our Tri-STAR platform, targeting difficult-to-treat ‘cold’ tumors. Marengo is eligible to receive up to $1.2 billion plus tiered royalties to progress our mission: The right activation of the right immune cells to promote lifelong protection against cancer Learn more: https://lnkd.in/e4h9-kqu #Biotech #immunooncology #Partnership #Innovation #CancerResearch #Oncology #MarengoTherapeutics #Ipsen
-
Exciting News! Today Marengo Therapeutics jointly announced our expanded partnership with Ipsen to advance precision T cell engagers from our Tri-STAR platform, targeting difficult-to-treat ‘cold’ tumors. Marengo is eligible to receive up to $1.2 billion plus tiered royalties to progress our mission: The right activation of the right immune cells to promote lifelong protection against cancer Learn more: https://lnkd.in/e4h9-kqu #Biotech #immunooncology #Partnership #Innovation #CancerResearch #Oncology #MarengoTherapeutics #Ipsen
-
Join Marengo's CEO Zhen Su, MD MBA, who will be speaking at the upcoming Longwood Healthcare Leaders Spring MIT event, June 17 - 18, 2024. More information: https://lnkd.in/exxKDits #longwoodhealthcareleaders #ceo #biotech
-
Two new team members joined Marengo in May: Please join us in welcoming Mark Jakubowicz and Keana Ramos Baptista. We are thrilled to have you with us! Want to join us? Check out our open roles: https://lnkd.in/eQCzHw7z